Industries > Pharma > Antidiarrheal Drugs Market Report to 2031
Antidiarrheal Drugs Market Report to 2031
By Type (Prescription Drugs, OTC (Over the Counter) Drugs), By End User (Children, Adults), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Antidiarrheal Drugs Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Antidiarrheal Drugs market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Antidiarrheal Drugs report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antidiarrheal Drugs Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Antidiarrheal Drugs Market by Type
• Prescription drugs
• OTC (over the counter) drugs
Antidiarrheal Drugs Market by end user
• Children
• Adults
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antidiarrheal Drugs Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antidiarrheal Drugs Market with forecasts for by type and by end user each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Antidiarrheal Drugs Market report helps you
In summary, our 250+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Antidiarrheal Drugs Market, with forecasts for by type, and end user each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antidiarrheal Drugs market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Antidiarrheal Drugs of the major companies involved in the Antidiarrheal Drugs Market. Some of the company’s profiled in this report include-
• Lupin,
• Pfizer, Inc.
• Actelion Pharmaceuticals Ltd
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals
• Perrigo Company Plc
• Johnson & Johnson,
• Proctor & Gamble
• Novartis AG
• Sanofi Aventis
• Merck & Co.,
• Bayer AG
• Eli Lilly and Co.
• Mylan N.V.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Antidiarrheal Drugs Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antidiarrheal Drugs Market Report to 2031: By Type (Prescription Drugs, OTC (Over The Counter) Drugs), By End User (Children, Adults). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Antidiarrheal Drugs Market
2.1. Antidiarrheal Drugs Market Definition
2.2. By Type Submarkets Definitions
2.3. By End User Submarkets Definitions
3. Antidiarrheal Drugs Market Overview
3.1. Global Antidiarrheal Drugs Market Size and Forecast by Region
3.2. Global Antidiarrheal Drugs Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Cases of Diarrhea in Developing Countries.
3.3.1.2. Growing Demand for Anti-Diarrheal Drugs
3.3.1.3. Rising Prevalence Among Children and Ageing Population
3.3.2. Market Restraints/Challenges
3.3.2.1. Side-Effects Associated with Antidiarrhea Drug Such as Nausea, Vomiting, Dizziness, and Constipation
3.3.3. Opportunities
3.3.3.1. Increasing Awareness Among Population for Antidiarrheal Drugs.
3.3.3.2. FDA Encouraging Safety of Drugs.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antidiarrheal Drugs Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Prescription drugs
4.2.1.1. Codeine, Diphenoxylate, and Colesevelam are some of the prescribed antidiarrheal drugs.
4.3. OTC (over the counter) drugs
4.3.1.1. Increasing use of Loperamide and Bismuth subsalicylate, as it helps to control severe symptoms.
5. Global Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 By End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Children
5.1.1.1. Increasing demand for antidiarrheal drugs among children.
5.1.2. Adults
5.1.2.1. Food born infection, travelling leads to more bacteria-related cases of acute diarrhea in elderly.
6. North America Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Antidiarrheal Drugs Market Size and Forecast By Type
6.3. North America Antidiarrheal Drugs Market Size and Forecast By End User
6.4. U.S. Antidiarrheal Drugs Market
6.4.1. Increasing elderly patients of acute diarrhea in the region.
6.5. Canada Antidiarrheal Drugs Market
6.5.1. Increasing risk of travelers’ diarrhea.
7. Europe Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Antidiarrheal Drugs Market Size and Forecast By Type
7.3. Europe Antidiarrheal Drugs Market Size and Forecast By End User
7.4. UK Antidiarrheal Drugs Market
7.4.1. Increasing child mortality rate due to diarrhea in the region.
7.5. Germany Antidiarrheal Drugs Market
7.5.1. Increasing use of over the counter (OTC) drugs in the region.
7.6. France Antidiarrheal Drugs Market
7.6.1. Increasing drug sales to treat gastroenteritis in the region.
7.7. Rest of Europe Antidiarrheal Drugs Market
8. Asia Pacific Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Antidiarrheal Drugs Market Size and Forecast By Type
8.3. Asia Pacific Antidiarrheal Drugs Market Size and Forecast By End User
8.4. China Antidiarrheal Drugs Market
8.4.1. Increasing ageing population and chances of diarrhea in the region.
8.5. India Antidiarrheal Drugs Market
8.5.1. Poor hygiene, malnutrition and inadequate breastfeeding among children increasing chances of diarrhea among children.
8.6. Japan Antidiarrheal Drugs Market
8.6.1. Antidiarrheal drugs prescription in the region is increasing.
8.7. Rest of Asia Pacific Antidiarrheal Drugs Market
9. Latin America Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Antidiarrheal Drugs Market Size and Forecast By Type
9.3. Latin America Antidiarrheal Drugs Market Size and Forecast By End User
9.3.1. Brazil Antidiarrheal Drugs Market
9.3.1.1. Factors such as climatic problems, poor hygiene, waterborne diseases, are contributing to increase diarrheal cases in the region.
9.3.2. Mexico Antidiarrheal Drugs Market
9.3.2.1. FDA approval for Aemcolo, to treat traveler diarrhea in the region.
9.3.3. Rest of Latin America Antidiarrheal Drugs Market
9.3.3.1. Increasing number of cases among children.
10. MEA Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Antidiarrheal Drugs Market Size and Forecast By Type
10.3. MEA Antidiarrheal Drugs Market Size and Forecast By End User
10.4. South Africa Antidiarrheal Drugs Market
10.4.1.1. Increasing cases of childhood diarrhea in the region.
10.5. Rest of MEA Antidiarrheal Drugs Market
10.5.1.1. Availability demand for antidiarrheal drugs in the region.
11. Companies in the Antidiarrheal Drugs Market
11.1. Lupin Laboratories Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.2.1. Net Revenue
11.1.3. Product Offerings
11.1.4. Recent Initiatives (2017-2020)
11.2. Pfizer, Inc.
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Actelion Pharmaceuticals Ltd
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. GlaxoSmithKline plc
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Glenmark Pharmaceuticals
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Perrigo Company Plc
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. Johnson & Johnson,
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. Proctor & Gamble
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. Novartis AG
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Sanofi Aventis
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antidiarrheal Drugs Market Drivers & Restraints 2021
Table 7. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 29. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 30. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 31. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table32. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 37. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 38. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 39. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 40. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 41. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 42. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 43. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 44. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 45. North America Antidiarrheal Drugs Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 46. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 47. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 48. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 49. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table50. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 51. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 52. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 53. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 54. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 55. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 56. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 57. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 58. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 59. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 60. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 61. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 62. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 63. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 64. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 65. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 66. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 67. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 68. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 69. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table70. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 71. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 72. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 73. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 74. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 75. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 76. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 77. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 78. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 79. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 80. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 81. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 94. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 95. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 100. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 111. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Leading 10 Antidiarrheal Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 157. Lupin Laboratories Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 158. Lupin Laboratories Inc Antidiarrheal Drugs Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 159. Pfizer, Inc. Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 160. Pfizer, Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 161. Pfizer, Inc. Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 162. Actelion Pharmaceuticals Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 163. Actelion Pharmaceuticals Ltd Antidiarrheal Drugs Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 164. Actelion Pharmaceuticals Ltd Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 165. GlaxoSmithKline plc Profile 2020 (CEO, HQ, Founded, Website)
Table 166. GlaxoSmithKline plc Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 167. GlaxoSmithKline plc Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 168. Glenmark Pharmaceuticals Profile 2020 (CEO, HQ, Founded, Website)
Table 169. Glenmark Pharmaceuticals Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 170. Perrigo Company Plc Profile 2020 (CEO, HQ, Founded, Website)
Table 171. Perrigo Company Plc Antidiarrheal Drugs Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 172 Perrigo Company Plc Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 173. Johnson & Johnson, Profile 2020 (CEO, HQ, Founded, Website)
Table 174. Johnson & Johnson Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 175. Proctor & Gamble Profile 2020 (CEO, HQ, Founded, Website)
Table 176. Proctor & Gamble Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 177. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 178. Novartis AG Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 179. Sanofi Aventis Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 180. Sanofi Aventis Total Company Sales 2015-2020(US$M, AGR %)
Table 181. Sanofi Aventis Product Offering (Segment, Product Offerings)
Table 182. Other Companies Involved in the Antidiarrheal Drugs Market (Company, Location)
LIST OF FIGURES
Figure 1. Antidiarrheal Drugs Market Type Overview
Figure 2. Antidiarrheal Drugs Market By Type Overview
Figure 3. Antidiarrheal Drugs Market by End User Overview
Figure 4 Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 14. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 15. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 16. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 17. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 18. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 19. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 20. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure21. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 24. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 25. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 26. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 27. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 28. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 29. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %)
Figure 30. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 31. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 32. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 33. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 34. North America Antidiarrheal Drugs Market Forecast By Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 40. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 45. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M)
Figure 50. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 51. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 52. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 53. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 54. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (Before COVID)
Figure 55. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 56. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 57. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 58. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 59. Europe Antidiarrheal Drugs Market Forecast By Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 60. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 61. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 62. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 63. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 64. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 65. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 66. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 67. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 68. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 69. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 70. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 71. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 72. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 73. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 74. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 75. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 77. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 80. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure81. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84 Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 85. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 86. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 87. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 88. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 89. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 90. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 91. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 92. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 93. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 94. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 95. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 96. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 97. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 98. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 99. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 100. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 101. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 102. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 103. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 104. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 105. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 106. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 107. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 108. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 109. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 114. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115 Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M)
Figure 119. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 120. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 121. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 122. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 123. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M)
Figure 124. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 125. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 126. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 127. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 128. Rest Of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 129. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 130. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 131. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 132. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 133. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M)
Figure 134. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M)
Figure 139. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 140. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 141. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 142. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 143. Rest Of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 144. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 145. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 146. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 147. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 148. Porter’s Five Force Analysis
Companies Mentioned
1. Lupin,
2. Pfizer, Inc.
3. Actelion Pharmaceuticals Ltd
4. GlaxoSmithKline plc
5. Glenmark Pharmaceuticals
6. Perrigo Company Plc
7. Johnson & Johnson,
8. Proctor & Gamble
9. Novartis AG
10. Sanofi Aventis
11. Merck & Co.,
12. Bayer AG
13. Eli Lilly and Co.
14. Mylan N.V.
15. Apricus Biosciences Inc.
16. Teva Pharmaceutical Industries Ltd
17. Johnson & Johnson Services
18. Biocodex, Inc.
19. Abbott Healthcare
20. Culturelle Health and Wellness
21. Piramal Enterprises
22. East India Pharmaceutical Works Limited
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Antidiarrheal Drugs Market
2.1. Antidiarrheal Drugs Market Definition
2.2. By Type Submarkets Definitions
2.3. By End User Submarkets Definitions
3. Antidiarrheal Drugs Market Overview
3.1. Global Antidiarrheal Drugs Market Size and Forecast by Region
3.2. Global Antidiarrheal Drugs Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Cases of Diarrhea in Developing Countries.
3.3.1.2. Growing Demand for Anti-Diarrheal Drugs
3.3.1.3. Rising Prevalence Among Children and Ageing Population
3.3.2. Market Restraints/Challenges
3.3.2.1. Side-Effects Associated with Antidiarrhea Drug Such as Nausea, Vomiting, Dizziness, and Constipation
3.3.3. Opportunities
3.3.3.1. Increasing Awareness Among Population for Antidiarrheal Drugs.
3.3.3.2. FDA Encouraging Safety of Drugs.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antidiarrheal Drugs Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Prescription drugs
4.2.1.1. Codeine, Diphenoxylate, and Colesevelam are some of the prescribed antidiarrheal drugs.
4.3. OTC (over the counter) drugs
4.3.1.1. Increasing use of Loperamide and Bismuth subsalicylate, as it helps to control severe symptoms.
5. Global Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 By End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Children
5.1.1.1. Increasing demand for antidiarrheal drugs among children.
5.1.2. Adults
5.1.2.1. Food born infection, travelling leads to more bacteria-related cases of acute diarrhea in elderly.
6. North America Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Antidiarrheal Drugs Market Size and Forecast By Type
6.3. North America Antidiarrheal Drugs Market Size and Forecast By End User
6.4. U.S. Antidiarrheal Drugs Market
6.4.1. Increasing elderly patients of acute diarrhea in the region.
6.5. Canada Antidiarrheal Drugs Market
6.5.1. Increasing risk of travelers’ diarrhea.
7. Europe Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Antidiarrheal Drugs Market Size and Forecast By Type
7.3. Europe Antidiarrheal Drugs Market Size and Forecast By End User
7.4. UK Antidiarrheal Drugs Market
7.4.1. Increasing child mortality rate due to diarrhea in the region.
7.5. Germany Antidiarrheal Drugs Market
7.5.1. Increasing use of over the counter (OTC) drugs in the region.
7.6. France Antidiarrheal Drugs Market
7.6.1. Increasing drug sales to treat gastroenteritis in the region.
7.7. Rest of Europe Antidiarrheal Drugs Market
8. Asia Pacific Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Antidiarrheal Drugs Market Size and Forecast By Type
8.3. Asia Pacific Antidiarrheal Drugs Market Size and Forecast By End User
8.4. China Antidiarrheal Drugs Market
8.4.1. Increasing ageing population and chances of diarrhea in the region.
8.5. India Antidiarrheal Drugs Market
8.5.1. Poor hygiene, malnutrition and inadequate breastfeeding among children increasing chances of diarrhea among children.
8.6. Japan Antidiarrheal Drugs Market
8.6.1. Antidiarrheal drugs prescription in the region is increasing.
8.7. Rest of Asia Pacific Antidiarrheal Drugs Market
9. Latin America Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Antidiarrheal Drugs Market Size and Forecast By Type
9.3. Latin America Antidiarrheal Drugs Market Size and Forecast By End User
9.3.1. Brazil Antidiarrheal Drugs Market
9.3.1.1. Factors such as climatic problems, poor hygiene, waterborne diseases, are contributing to increase diarrheal cases in the region.
9.3.2. Mexico Antidiarrheal Drugs Market
9.3.2.1. FDA approval for Aemcolo, to treat traveler diarrhea in the region.
9.3.3. Rest of Latin America Antidiarrheal Drugs Market
9.3.3.1. Increasing number of cases among children.
10. MEA Antidiarrheal Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Antidiarrheal Drugs Market Size and Forecast By Type
10.3. MEA Antidiarrheal Drugs Market Size and Forecast By End User
10.4. South Africa Antidiarrheal Drugs Market
10.4.1.1. Increasing cases of childhood diarrhea in the region.
10.5. Rest of MEA Antidiarrheal Drugs Market
10.5.1.1. Availability demand for antidiarrheal drugs in the region.
11. Companies in the Antidiarrheal Drugs Market
11.1. Lupin Laboratories Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.2.1. Net Revenue
11.1.3. Product Offerings
11.1.4. Recent Initiatives (2017-2020)
11.2. Pfizer, Inc.
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Actelion Pharmaceuticals Ltd
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. GlaxoSmithKline plc
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Glenmark Pharmaceuticals
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Perrigo Company Plc
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. Johnson & Johnson,
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. Proctor & Gamble
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. Novartis AG
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Sanofi Aventis
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antidiarrheal Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antidiarrheal Drugs Market Drivers & Restraints 2021
Table 7. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Prescription drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. OTC (over the counter) drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 29. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 30. Children Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 31. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table32. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35. Adults Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 37. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 38. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 39. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 40. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 41. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 42. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 43. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 44. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 45. North America Antidiarrheal Drugs Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 46. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 47. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 48. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 49. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table50. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 51. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 52. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 53. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 54. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 55. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 56. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 57. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 58. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 59. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 60. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 61. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 62. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 63. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 64. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 65. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 66. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 67. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 68. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 69. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table70. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 71. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 72. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 73. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 74. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 75. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 76. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 77. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 78. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 79. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 80. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 81. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 94. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 95. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 100. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105. Asia Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110. Asia Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 111. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115. Asia Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135. RoAPAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Leading 10 Antidiarrheal Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 157. Lupin Laboratories Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 158. Lupin Laboratories Inc Antidiarrheal Drugs Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 159. Pfizer, Inc. Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 160. Pfizer, Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 161. Pfizer, Inc. Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 162. Actelion Pharmaceuticals Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 163. Actelion Pharmaceuticals Ltd Antidiarrheal Drugs Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 164. Actelion Pharmaceuticals Ltd Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 165. GlaxoSmithKline plc Profile 2020 (CEO, HQ, Founded, Website)
Table 166. GlaxoSmithKline plc Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 167. GlaxoSmithKline plc Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 168. Glenmark Pharmaceuticals Profile 2020 (CEO, HQ, Founded, Website)
Table 169. Glenmark Pharmaceuticals Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 170. Perrigo Company Plc Profile 2020 (CEO, HQ, Founded, Website)
Table 171. Perrigo Company Plc Antidiarrheal Drugs Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 172 Perrigo Company Plc Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 173. Johnson & Johnson, Profile 2020 (CEO, HQ, Founded, Website)
Table 174. Johnson & Johnson Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 175. Proctor & Gamble Profile 2020 (CEO, HQ, Founded, Website)
Table 176. Proctor & Gamble Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 177. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 178. Novartis AG Antidiarrheal Drugs Product Offering (Segment, Product Offerings)
Table 179. Sanofi Aventis Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 180. Sanofi Aventis Total Company Sales 2015-2020(US$M, AGR %)
Table 181. Sanofi Aventis Product Offering (Segment, Product Offerings)
Table 182. Other Companies Involved in the Antidiarrheal Drugs Market (Company, Location)
LIST OF FIGURES
Figure 1. Antidiarrheal Drugs Market Type Overview
Figure 2. Antidiarrheal Drugs Market By Type Overview
Figure 3. Antidiarrheal Drugs Market by End User Overview
Figure 4 Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Antidiarrheal Drugs Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 14. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 15. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 16. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 17. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 18. Antidiarrheal Drugs Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 19. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 20. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure21. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Regional Antidiarrheal Drugs Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 24. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 25. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 26. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 27. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 28. North America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 29. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %)
Figure 30. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 31. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 32. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 33. North America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 34. North America Antidiarrheal Drugs Market Forecast By Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 40. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. US Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 45. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. Canada Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M)
Figure 50. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 51. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 52. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 53. Europe Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 54. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (Before COVID)
Figure 55. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 56. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 57. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 58. Europe Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 59. Europe Antidiarrheal Drugs Market Forecast By Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 60. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 61. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 62. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 63. Europe Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 64. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 65. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 66. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 67. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 68. UK Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 69. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 70. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 71. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 72. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 73. Germany Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 74. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 75. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 77. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. France Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 80. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure81. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Rest of Europe Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84 Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 85. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 86. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 87. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 88. Asia-Pacific Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 89. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 90. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 91. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 92. Asia-Pacific Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 93. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 94. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 95. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 96. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 97. Asia-Pacific Antidiarrheal Drugs Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 98. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 99. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 100. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 101. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 102. China Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 103. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 104. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 105. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 106. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 107. India Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 108. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 109. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. Japan Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 114. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115 Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. Rest of APAC Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M)
Figure 119. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 120. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 121. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 122. Middle East Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 123. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M)
Figure 124. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 125. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 126. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 127. Middle East Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 128. Rest Of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 129. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 130. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 131. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 132. Rest of Middle East Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 133. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M)
Figure 134. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Latin America Antidiarrheal Drugs Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M)
Figure 139. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 140. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 141. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 142. Latin America Antidiarrheal Drugs Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 143. Rest Of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %)
Figure 144. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 145. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 146. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 147. Rest of Latin America Antidiarrheal Drugs Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 148. Porter’s Five Force Analysis
Companies Mentioned
1. Lupin,
2. Pfizer, Inc.
3. Actelion Pharmaceuticals Ltd
4. GlaxoSmithKline plc
5. Glenmark Pharmaceuticals
6. Perrigo Company Plc
7. Johnson & Johnson,
8. Proctor & Gamble
9. Novartis AG
10. Sanofi Aventis
11. Merck & Co.,
12. Bayer AG
13. Eli Lilly and Co.
14. Mylan N.V.
15. Apricus Biosciences Inc.
16. Teva Pharmaceutical Industries Ltd
17. Johnson & Johnson Services
18. Biocodex, Inc.
19. Abbott Healthcare
20. Culturelle Health and Wellness
21. Piramal Enterprises
22. East India Pharmaceutical Works Limited
Companies Profiled in the Report
1. Lupin Laboratories Inc.
2. Pfizer, Inc.
3. Actelion Pharmaceuticals Ltd
4. GlaxoSmithKline plc
5. Glenmark Pharmaceuticals
6. Perrigo Company Plc
7. Johnson & Johnson,
8. Proctor & Gamble
9. Novartis AG
10. Sanofi Aventis
11. Merck & Co.,
12. Bayer AG
13. Eli Lilly and Co.
14. Mylan N.V.
List of Companies Mentioned in the Report
1. Lupin,
2. Pfizer, Inc.
3. Actelion Pharmaceuticals Ltd
4. GlaxoSmithKline plc
5. Glenmark Pharmaceuticals
6. Perrigo Company Plc
7. Johnson & Johnson,
8. Proctor & Gamble
9. Novartis AG
10. Sanofi Aventis
11. Merck & Co.,
12. Bayer AG
13. Eli Lilly and Co.
14. Mylan N.V.
15. Apricus Biosciences Inc.
16. Teva Pharmaceutical Industries Ltd
17. Johnson & Johnson Services
18. Biocodex, Inc.
19. Abbott Healthcare
20. Culturelle Health and Wellness
21. Piramal Enterprises
22. East India Pharmaceutical Works Limited
List of Organizations Mentioned in the Report
1. World Health Organization
2. The European Medicines Agency (EMA)
3. American College of Gastroenterology
4. Infectious Diseases & Antimicrobial Agents
5. US Food & Drug Administration
6. US National Library of Medicine
7. National Institutes of Health
8. American Academy of Family Physicians
9. National Center for Biotechnology information
10. Veterans Administration Medical Center
11. Elephant Care International
12. National Association for Biomedical Research
13. Center for Disease Control and Prevention CDC
14. Journal of the American college of Cardiology
15. The British Diabetic Association
16. National Association of Orthopaedic Nurses
17. National Foundation for Infectious Diseases.
18. Clinical Infectious Diseases
19. American Association for Cancer Research.
20. Center for Diseases Dynamics, Economics & Policy (CDDEP)
21. The Global Health Security Agenda (GHSA)
1. Lupin Laboratories Inc.
2. Pfizer, Inc.
3. Actelion Pharmaceuticals Ltd
4. GlaxoSmithKline plc
5. Glenmark Pharmaceuticals
6. Perrigo Company Plc
7. Johnson & Johnson,
8. Proctor & Gamble
9. Novartis AG
10. Sanofi Aventis
11. Merck & Co.,
12. Bayer AG
13. Eli Lilly and Co.
14. Mylan N.V.
List of Companies Mentioned in the Report
1. Lupin,
2. Pfizer, Inc.
3. Actelion Pharmaceuticals Ltd
4. GlaxoSmithKline plc
5. Glenmark Pharmaceuticals
6. Perrigo Company Plc
7. Johnson & Johnson,
8. Proctor & Gamble
9. Novartis AG
10. Sanofi Aventis
11. Merck & Co.,
12. Bayer AG
13. Eli Lilly and Co.
14. Mylan N.V.
15. Apricus Biosciences Inc.
16. Teva Pharmaceutical Industries Ltd
17. Johnson & Johnson Services
18. Biocodex, Inc.
19. Abbott Healthcare
20. Culturelle Health and Wellness
21. Piramal Enterprises
22. East India Pharmaceutical Works Limited
List of Organizations Mentioned in the Report
1. World Health Organization
2. The European Medicines Agency (EMA)
3. American College of Gastroenterology
4. Infectious Diseases & Antimicrobial Agents
5. US Food & Drug Administration
6. US National Library of Medicine
7. National Institutes of Health
8. American Academy of Family Physicians
9. National Center for Biotechnology information
10. Veterans Administration Medical Center
11. Elephant Care International
12. National Association for Biomedical Research
13. Center for Disease Control and Prevention CDC
14. Journal of the American college of Cardiology
15. The British Diabetic Association
16. National Association of Orthopaedic Nurses
17. National Foundation for Infectious Diseases.
18. Clinical Infectious Diseases
19. American Association for Cancer Research.
20. Center for Diseases Dynamics, Economics & Policy (CDDEP)
21. The Global Health Security Agenda (GHSA)
Download sample pages
Complete the form below to download your free sample pages for Antidiarrheal Drugs Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Antidiarrheal Drugs Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
